Here are the one year history charts of Gambro A and Gambro B shares from the Gambro web site.

May 2000 - Amgen's Chairman and CEO Gordon M. Binder has responded to the letter sent by NRAA President Terry Bahr. You can view it on this page from Dialysis & Transplantation, but you must scroll down to the second story.

May 1, 2000 - The Board of Directors of the National Renal Administrators Association (NRAA) has sent a letter expressing its views on the recent Epogen™ price increase to Amgen CEO Gordon Binder. The letter was signed by NRAA President Terry Bahr.

February 28, 2000 - Amgen announced on February 24 that it was increasing the price of EPO by 3.9 percent. It was the drug's first price increase since it was introduced 11 years ago. The news of the price increase drove the Amgen stock price lower.

Dialysis centers, which finally won a small increase in reimbursement for dialysis treatments from Congress recently, will receive no increase in EPO reimbursement from Medicare. The news of the price increase drove the stock prices of all the major dialysis providers down.

Total Renal Care (TRC), which has been struggling to avoid any further earnings surprises, immediately issued a press release about the impact of the EPO price increase on their projected earnings. The stock price of Total Renal Care fell to another all time low ($3.50) on Friday, February 25th. It is trading for as low as $2.75 on Monday, February 28.

The stock price of Fresenius Medical Care AG also fell 4% on the news.